Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)

Market Cap	24.09B -16.2%
Revenue (ttm)	14.78B +27.7%
Net Income	1.24B +117.1%
EPS	5.36 +117.1%
Shares Out	231.00M
PE Ratio	19.47
Forward PE	n/a
Dividend	2.10 (1.98%)
Ex-Dividend Date	Nov 17, 2025

Volume	291,864
Average Volume	344,132
Open	n/a
Previous Close	106.10
Day's Range	103.80 - 107.70
52-Week Range	92.40 - 147.50
Beta	-0.40
RSI	55.32
Earnings Date	Apr 27, 2026

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories that include oncology, hematology, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointesti...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 4,771
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In fiscal year 2025, Beacon Pharmaceuticals's revenue was 12.54 billion, an increase of 17.20% compared to the previous year's 10.70 billion. Earnings were 946.51 million, an increase of 81.67%.